Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00017121 · ClinicalTrials.gov registry record · Phase 1
Inhaled Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
A Phase 1 study of Metastatic Cancer and Melanoma (Skin), sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 20
- Study locations
NCT00017121: Completed Phase 1 study of Metastatic Cancer and Melanoma (Skin), sponsored by Alliance for Clinical Trials in Oncology.
NCT00017121 is a Phase 1 study of Metastatic Cancer and Melanoma (Skin) that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 40 participants, below the 444-participant average among 109 other Metastatic Cancer trials with a reported enrollment target (91% lower). The trial reports 20 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00017121, a Phase 1 study of Metastatic Cancer and Melanoma (Skin), has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Inhaling sargramostim may interfere with the growth of tumor cells and may be an effective treatment for melanoma that has spread to the lung. PURPOSE: This phase I trial is studying the side effects and best dose of inhaled sargramostim in treating patients with melanoma that is metastatic to the lung.
Conditions Studied
Interventions
- BIOLOGICAL sargramostim
Study Locations (20)
Illinois
- Rush-Copley Cancer Care Center - Aurora
- St. Joseph Medical Center - Bloomington
- Graham Hospital - Canton
- Memorial Hospital - Carthage
- Eureka Community Hospital - Eureka
- Galesburg Clinic - Galesburg
- Galesburg Cottage Hospital - Galesburg
- Mason District Hospital - Havana
- Hopedale Medical Complex - Hopedale
- Joliet Oncology-Hematology Associates, Limited - West - Joliet
- Kewanee Hospital - Kewanee
- McDonough District Hospital - Macomb
- BroMenn Regional Medical Center - Normal
- Community Cancer Center - Normal
- Community Hospital of Ottawa - Ottawa
- Oncology Hematology Associates of Central Illinois, PC - Ottawa - Ottawa
- Cancer Treatment Center at Pekin Hospital - Pekin
- Proctor Hospital - Peoria
Arizona
- Mayo Clinic Scottsdale - Scottsdale
Florida
- Mayo Clinic - Jacksonville - Jacksonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2002-05 |
| Est. Completion | 2012-11 |
| Phase | Phase 1 |
What the finished NCT00017121 record still lists
NCT00017121 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 444-participant average among 109 other Metastatic Cancer trials with a reported enrollment target (91% lower).
The record links to 2 conditions, with Metastatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which sargramostim is the first listed.
NCT00017121 names 20 study sites across 3 states, led by Illinois, Arizona, Florida.
Frequently Asked Questions
What is clinical trial NCT00017121 about?
NCT00017121 is a clinical study titled "Inhaled Sargramostim in Treating Patients With Melanoma Metastatic to the Lung". RATIONALE: Inhaling sargramostim may interfere with the growth of tumor cells and may be an effective treatment for melanoma that has spread to the lung. PURPOSE: This phase I trial is studying the side effects and best dose of inhaled sargramostim in treating patients with melanoma that is metasta...
What is the current status of trial NCT00017121?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2002-05. Estimated completion is 2012-11.
What conditions does trial NCT00017121 study?
This clinical trial studies the following conditions: Metastatic Cancer, Melanoma (Skin).
What interventions are being tested in trial NCT00017121?
The interventions under investigation include: sargramostim (BIOLOGICAL).
Who is sponsoring clinical trial NCT00017121?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00017121 being conducted?
This trial has 20 study locations across Arizona, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00017121's enrollment target sits among peer trials
40 67th of 109 higher than 38 of 109 other Metastatic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
RECRUITING · Phase 1
-
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
RECRUITING · Phase 1
-
Y-NM600 in Patients Receiving Anti-PD-1 or Anti-PD-L1 for Metastatic Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia